AIF1 and central nervous system cancer: Furthermore, via the use of an Iba-1 antibody, a marker of inflammation, and immunohistochemistry, in an in vivo rodent glioblastoma model (GL261 glioma cells), it was revealed that the degree of Iba-1 positive microglia had increased following N-type inhibition.